Intercept Pharmaceuticals, Inc.
ICPT · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $89 | $84 | $68 | $77 |
| % Growth | 6.1% | 23.2% | -12% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $89 | $84 | $68 | $77 |
| % Margin | 99.8% | 99.8% | 99.7% | 100% |
| R&D Expenses | $42 | $37 | $42 | $41 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $45 | $53 | $58 | $55 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $87 | $91 | $99 | $96 |
| Operating Income | -$5 | -$7 | -$32 | -$19 |
| % Margin | -5.2% | -8.5% | -46.5% | -24.5% |
| Other Income/Exp. Net | -$4 | $4 | -$0 | $124 |
| Pre-Tax Income | -$3 | -$3 | -$32 | -$18 |
| Tax Expense | $5 | $3 | -$2 | $3 |
| Net Income | -$3 | -$6 | -$30 | -$20 |
| % Margin | -3.1% | -7% | -43.5% | -26.4% |
| EPS | -0.067 | -0.14 | -0.71 | -0.49 |
| % Growth | 52.3% | 80.3% | -44.9% | – |
| EPS Diluted | -0.067 | -0.14 | -0.71 | -0.49 |
| Weighted Avg Shares Out | 42 | 42 | 42 | 41 |
| Weighted Avg Shares Out Dil | 42 | 42 | 42 | 41 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $3 | $3 | $3 |
| Interest Expense | $2 | $3 | $3 | $3 |
| Depreciation & Amortization | $0 | $4 | $3 | $4 |
| EBITDA | $5 | $1 | -$27 | -$15 |
| % Margin | 5.8% | 1.3% | -39% | -19.1% |